Previous Article | Next Article 
Journal of Clinical Microbiology, August 2007, p. 2701-2703, Vol. 45, No. 8
0095-1137/07/$08.00+0 doi:10.1128/JCM.00642-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Nonsporulating Clinical Isolate Identified as Petromyces alliaceus (Anamorph Aspergillus alliaceus) by Morphological and Sequence-Based Methods
S. Arunmozhi Balajee,1*
Mark D. Lindsley,1
Naureen Iqbal,1
James Ito,2
Peter G. Pappas,3 and
Mary E. Brandt1
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia,1
City of Hope National Medical Center, Duarte, California,2
Division of Infectious Diseases, University of Alabama at Birmingham, Alabama3
Received 22 March 2007/
Returned for modification 3 May 2007/
Accepted 22 May 2007

ABSTRACT
Concerted morphological and sequencing-based strategies revealed
the identity of a nonsporulating clinical isolate as
Petromyces alliaceus (anamorph
Aspergillus alliaceus). This rare
Aspergillus sp. was recovered as the etiological agent of invasive pulmonary
aspergillosis and had reduced in vitro susceptibilities to amphotericin
B and caspofungin, which correlated with clinical failure of
therapy.

TEXT
A 54-year-old woman underwent sibling donor allogeneic hematopoietic
cell transplantation for refractory pre-B acute lymphoblastic
leukemia. On day 2 posttransplantation, amphotericin B lipid
complex (ABLC) therapy (1 mg/kg daily) was begun as antifungal
prophylaxis. Glucocorticosteroids were begun immediately posttransplantation
for graft-versus-host disease prophylaxis and continued through
her hospital course. On day 10 itraconazole (ITZ) was substituted
for the ABLC because of nephrotoxicity; on day 26 the patient
developed cardiopulmonary failure and required intubation. A
chest radiograph at that time revealed pulmonary infiltrates.
Bronchoscopy revealed serosanguinous fluid, and cytologic examination
of the bronchoalveolar lavage fluid showed branching septate
hyphae; however, a KOH smear did not reveal any hyphae, nor
did the culture grow any fungus at this time. A diagnosis of
probable invasive pulmonary fungal infection was made based
upon the EORTC/MSG criteria (i.e., the European Organization
for Research and Treatment of Cancer/Mycoses Study Group [
1])
since the first bronchoscopy demonstrated fungal hyphae on cytologic
examination, and the second bronchoscopy grew out the mold.
On day 27, ITZ treatment was discontinued, and ABLC (5 mg/kg
daily) and caspofungin (CAS; 70 mg loading dose, followed by
50 mg daily) treatment were initiated. A serum
Aspergillus galactomannan
enzyme immunoassay on day 28 was negative; this could be, as
previously shown (
9), because the patient was on prophylactic
antifungal therapy prior to the onset of infection. On day 38
a second bronchoscopy was performed; the bronchoalveolar lavage
fluid was negative for fungal elements as determined by direct
microscopy. However, the fluid grew a "white, fuzzy mold" that
was reported as "nonsporulating mold." A chest computed tomography
scan obtained on day 43 revealed three cavitary lesions with
patchy areas of consolidation and diffuse interstitial infiltrates.
The patient continued to deteriorate and died on day 48. An
autopsy was not performed. The patient had been on high doses
of corticosteroids throughout her posttransplantation period.
No further attempt was made to identify the fungal isolate, and the organism was sent to the Fungal Reference Unit, Centers for Disease Control and Prevention, for detailed investigation as part of a surveillance study for invasive fungal infections in transplant recipients (10). The isolate was subjected to both morphological and molecular identification. Genomic DNA was extracted from the fungus, and the internal transcribed spacer regions (ITS) and 28S ribosomal regions were PCR amplified and sequenced as described previously (7, 8). Primer sequences used for both PCR and sequencing were as follows: forward, 5'-TCCTCCGCTTATTGATATGC and GGAAGTAAAAGTGGTAACAAGG (ITS4 and ITS5 [8]) for the ITS regions; and forward, 5'-GCATATCAATAAGCGGAGGAAAAG, and reverse, 5'-GGTCCGTGTTTCAAGACGG, for the D1 and D2 regions of the 28S rRNA (7). The resultant sequences (amplicon sizes of 594 and 577 bp for the ITS and 28S regions, respectively) were then compared to the available sequences in the GenBank database using the program BLASTn. The results revealed that the sequence was 100% homologous to Petromyces alliaceus (GenBank accession nos. AF149755 and AF149754) and 98% homologous to P. albertensis (GenBank accession no. AJ005673) and A. lanosus (GenBank accession no. AF203810) in the ITS region. When the more conserved 28S region was analyzed, the queried sequence was 100% homologous to P. alliaceus (GenBank accession no. PAU15496 and PAU28913), P. albertensis (GenBank accession no. PAU28910), and A. lanosus (GenBank accession no. ALU28914).
The sequences generated in this study have been submitted to GenBank under accession numbers EF447422 and EF447423.
Subsequently, the fungus was subcultured on Sabouraud dextrose agar (SDA; Becton Dickinson, Sparks, MD) supplemented with chloramphenicol and gentamicin at 25°C. The isolate grew predominantly as sterile hyphae interspersed with large ellipsoidal to cylindrical dark brown ascomata produced directly from the vegetative hyphae (Fig. 1a and b). Microscopic examinations of sections of these structures revealed that they were composed of sclerenchymatous tissue and were devoid of spores. Asexual sporulation was induced by culturing the isolate on SDA (without antibiotics) at 25°C in the presence of a constant supply of light. Under these conditions, the isolate produced orange yellow conidial heads indicative of the genus Aspergillus. Conidiophores were smooth with globose vesicles that gave rise to radiating, biseriate conidial heads producing smooth-walled, globose conidia (Fig. 1d). Figure 1c shows colonies growing from three-point inoculation that is used typically for Penicillium and Aspergillus species identification. The isolate grew well at 30, 35, and 37°C and sporulated abundantly in the presence of light.
The hallmark of
P. alliaceus is the production of ascomata,
whereas
A. lanosus does not produce ascomata; furthermore,
P. albertensis is now considered synonymous with
P. alliaceus (
14).
Although not observed in this study,
P. alliaceus upon prolonged
incubation (several months) is known to produce ascocarps within
the stromata (
6). Thus, with the combined phenotypic and genotypic
evidence, the unknown fungal isolate was identified as
P. alliaceus.
The teleomorphic species
P. alliaceus is one of only three members
assigned to the genus
Petromyces. Although
Petromyces spp. have
been isolated from surfaces of plants and soil, the
P. alliaceus is rarely recovered from an invasive fungal infection and has
been previously isolated from a case of chronic otorrhea (drainage
from the auditory canal).
Petromyces alliaceus produces a variety
of secondary metabolites, including ochratoxin A and B. Although
the anamorph of the teleomorphic genus
Petromyces was originally
assigned to the
Aspergillus section
Circumdati, recent chemotaxonomic
and genotypic evidence places this genus in
Aspergillus section
Flavi, whose members often produce sclerotia (
13,
14).
The in vitro susceptibilities of P. alliaceus to the antifungal drugs amphotericin B (AmB), natamycin (NAT), voriconazole (VRZ), ITZ, and CAS were determined by the broth microdilution method as outlined in CLSI document M38A (5) and for all drugs except NAT by the Etest methodologies (12). The results of the broth microdilution method showed that the antifungal drug MICs were high (AmB, 8 µg/ml; NAT, >32 µg/ml; ITZ, 0.125 µg/ml; and 1 µg/ml, VRZ) for the isolate and that the minimum effective concentration (defined as the minimum concentration of CAS that produced morphological alterations as viewed under a light microscope) was >8 µg/ml for CAS. These MICs were reproducible (the analyses were repeated twice with similar results). The Etest MICs were comparable with an MIC of >32 µg/ml for both AmB and CAS. The patient failed therapy with both ABLC and CAS, and this correlated well with the high in vitro MICs for both of these antifungals. Higher MICs for the cell wall active drugs (AmB, NAT, and CAS) may indicate differences in cell wall architecture in this previously unrecognized Aspergillus isolate.
It is being increasingly regarded that traditional approaches to fungal identification will gradually be replaced by DNA-based identification methods (11). While P. alliaceus isolated in the present study was at first refractory to classical identification (because of the absence of sporulation), morphologically identifiable features were eventually induced by growth in different conditions, media, and temperatures. Although molecular methods directed the identification, delineation between the two closely related species A. lanosus and P. alliaceus was secured by the observation of ascomata produced by P. alliaceus.
Genotyping methods are more rapid and easier to perform than phenotypic methods, and yet the latter approach has and will continue to be used in the clinical microbiology laboratory due to its simplicity, economy, and reliable identification most of the time. Thus, a prudent approach to fungal identification would be to augment, rather than to replace, classical methods with molecular methods. Another advantage of pursuing morphology-based methods for identifying aspergilli is that antifungal susceptibility profiles can be generated with the induction of a sporulating phenotype; as shown in this study, this information may be important in guiding treatment strategies given the low susceptibility of this isolate to several antifungal agents.
Although isolation of Petromyces as a cause of invasive infection is rare, there appear to be increasing reports of such previously unrecognized aspergilli with low susceptibilities to antifungal agents in clinical settings (2-4). The present study highlights two important, but often overlooked factors: (i) classical methods, if applied appropriately, have a sustained and significant role in the clinical microbiology laboratory, and (ii) the identification of "nonsporulating" filamentous aspergilli from ultra-high-risk patients may be important, given the reduced susceptibility of the P. alliaceus strain isolated here.

ACKNOWLEDGMENTS
We thank the members of the TransNet (surveillance for invasive
fungal infections in transplant recipients) Study Group from
the University of Alabama at Birmingham, the Centers for Disease
Control and Prevention, and the participating sites.
The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC.

FOOTNOTES
* Corresponding author. Mailing address: Mycotic Diseases Branch, Centers for Disease Control and Prevention, Mail Stop-G 11, 1600 Clifton Road, Atlanta, GA 30333. Phone: (404) 639-3337. Fax: (404) 639-3546. E-mail:
fir3{at}cdc.gov 
Published ahead of print on 30 May 2007. 

REFERENCES
1 - Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14.[CrossRef][Medline]
2 - Balajee, S. A., J. Gribskov, M. Brandt, J. Ito, A. Fothergill, and K. A. Marr. 2005. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J. Clin. Microbiol. 43:5996-5999.[Abstract/Free Full Text]
3 - Balajee, S. A., J. L. Gribskov, E. Hanley, D. Nickle, and K. A. Marr. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4:625-632.[Abstract/Free Full Text]
4 - Balajee, S. A., D. Nickle, J. Varga, and K. A. Marr. 2006. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot. Cell 5:1705-1712.[Abstract/Free Full Text]
5 - Clinical Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: approved standard M38-A. CLSI, Wayne, PA.
6 - Klich, M. A. 2002. Identification of common Aspergillus species, vol. 1. Centralbureau voor Schimmelcultures, Utrecht, The Netherlands.
7 - Kurtzman, C. P., and C. J. Robnett. 1997. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5' end of the large-subunit (26S) ribosomal DNA gene. J. Clin. Microbiol. 35:1216-1223.[Abstract]
8 - Larena, I., O. Salazar, V. Gonzalez, M. C. Julian, and V. Rubio. 1999. Design of a primer for ribosomal DNA internal transcribed spacer with enhanced specificity for ascomycetes. J. Biotechnol. 75:187-194.[CrossRef][Medline]
9 - Marr, K. A., and W. Leisenring. 2005. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin. Infect. Dis. 41(Suppl. 6):S381-S386.[CrossRef][Medline]
10 - Morgan, J., K. A. Wannemuehler, K. A. Marr, S. Hadley, D. P. Kontoyiannis, T. J. Walsh, S. K. Fridkin, P. G. Pappas, and D. W. Warnock. 2005. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. 43(Suppl. 1):S49-S58.[CrossRef][Medline]
11 - Odds, F. C. 2003. Reflections on the question: what does molecular mycology have to do with the clinician treating the patient? Med. Mycol. 41:1-6.[Medline]
12 - Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, and D. J. Diekema. 2003. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn. Microbiol. Infect. Dis. 45:241-244.[CrossRef][Medline]
13 - Rigo, K., J. Varga, B. Toth, J. Teren, A. Mesterhazy, and Z. Kozakiewicz. 2002. Evolutionary relationships within Aspergillus section Flavi based on sequences of the intergenic transcribed spacer regions and the 5.8S rRNA gene. J. Gen. Appl. Microbiol. 48:9-16.[CrossRef][Medline]
14 - Varga, J., B. Toth, E. Kevei, A. Palagyi, and Z. Kozakiewicz. 2000. Analysis of genetic variability within the genus Petromyces. Antonie Leeuwenhoek 77:83-89.[CrossRef][Medline]
Journal of Clinical Microbiology, August 2007, p. 2701-2703, Vol. 45, No. 8
0095-1137/07/$08.00+0 doi:10.1128/JCM.00642-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Brandt, M. E., Gade, L., McCloskey, C. B., Balajee, S. A.
(2009). Atypical Aspergillus flavus Isolates Associated with Chronic Azole Therapy. J. Clin. Microbiol.
47: 3372-3375
[Abstract]
[Full Text]
-
Balajee, S. A., Borman, A. M., Brandt, M. E., Cano, J., Cuenca-Estrella, M., Dannaoui, E., Guarro, J., Haase, G., Kibbler, C. C., Meyer, W., O'Donnell, K., Petti, C. A., Rodriguez-Tudela, J. L., Sutton, D., Velegraki, A., Wickes, B. L.
(2009). Sequence-Based Identification of Aspergillus, Fusarium, and Mucorales Species in the Clinical Mycology Laboratory: Where Are We and Where Should We Go from Here?. J. Clin. Microbiol.
47: 877-884
[Full Text]
-
Balajee, S.A., Houbraken, J., Verweij, P.E., Hong, S-B., Yaghuchi, T., Varga, J., Samson, R.A.
(2007). Aspergillus species identification in the clinical setting. SIM
59: 39-46
[Abstract]
[Full Text]